Prostatype Genomics offers prostate cancer patients a decision support for the most optimal treatment option!
We developed a test system called 'Prostatype® Test System'. The system is based on a gene expression test, which measures the expression of three carefully selected embryonic stem cell genes in prostate cancer core needle biopsies. In conjunction with currently used clinical parameters, the PrTS predicts overall survival in relation to treatment.
The Prostatype® Test System helps to choose the optimal treatment strategy for each patient. This secures quality of life for patients with a low risk tumor without jeopardizing safety for patients with aggressive tumors.
We developed a test system called 'Prostatype® Test System'. The system is based on a gene expression test, which measures the expression of three carefully selected embryonic stem cell genes in prostate cancer core needle biopsies. In conjunction with currently used clinical parameters, the PrTS predicts overall survival in relation to treatment.
The Prostatype® Test System helps to choose the optimal treatment strategy for each patient. This secures quality of life for patients with a low risk tumor without jeopardizing safety for patients with aggressive tumors.
Location: Sweden, Solna kommun
Employees: 11-50
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | Stockholm ... | sting.co |
Mentions in press and media 27
| Date | Title | Description |
| 19.04.2024 | Prostatype Genomics announces outcome of exercise of warrants of series 3 (TO3) | Prostatype Genomics announces outcome of exercise of warrants of series 3 (TO3) Fri, Apr 19, 2024 19:25 CET Report this content Prostatype Genomics AB ("Prostatype Genomics" or the "Company") today announces the outcome ... |
| 18.04.2024 | Prostatype Genomics announces very strong interim results from long-term follow-up study with Prostatype® in Uppsala | Prostatype Genomics announces very strong interim results from long-term follow-up study with Prostatype® in Uppsala Thu, Apr 18, 2024 13:06 CET Report this content Prostatype Genomics AB ("Prostatype Genomics" or the "Compan... |
| 17.04.2024 | Prostatype Genomics updates on significant progress in the US study with Prostatype® | Prostatype Genomics updates on significant progress in the US study with Prostatype® Wed, Apr 17, 2024 12:45 CET Report this content Prostatype Genomics AB (”Prostatype Genomics” or ”the Company”) announces that the US study with Prostatype... |
| 16.04.2024 | Prostatype Genomics announces strong positive final results from multicentre study with Prostatype® in Spain | Prostatype Genomics announces strong positive final results from multicentre study with Prostatype® in Spain Tue, Apr 16, 2024 17:13 CET Report this content Prostatype Genomics (”Prostatype Genomics” or ”the Company”) announces that the ret... |
| 05.04.2024 | The exercise period for Prostatype Genomic’s warrants of series 3 begins today | The exercise period for Prostatype Genomic’s warrants of series 3 begins today Fri, Apr 05, 2024 08:00 CET Report this content The exercise period for the warrants of series 3 (the "Warrants" or “TO3”) issued in connection with Pr... |
| 02.04.2024 | Prostatype Genomics enters into collaboration with Professor E. David Crawford, MD, University of California San Diego, in preparation for the commercial launch of Prostatype® in the United States | Prostatype Genomics enters into collaboration with Professor E. David Crawford, MD, University of California San Diego, in preparation for the commercial launch of Prostatype® in the United States Tue, Apr 02, 2024 10:57 CET Report this con... |
| 11.03.2024 | Prostatype Genomics publishes newsletter on US progress and the long-term follow-up study in Uppsala | Prostatype Genomics publishes newsletter on US progress and the long-term follow-up study in Uppsala Mon, Mar 11, 2024 09:46 CET Report this content Prostatype Genomics today publishes a newsletter for January–February 2024 with a CEO inter... |
| 15.02.2024 | Prostatype Genomics publishes year-end report for 2023 | Prostatype Genomics publishes year-end report for 2023 Thu, Feb 15, 2024 08:00 CET Report this content Prostatype Genomics AB today publishes its year-end report for the full year 2023, including the interim report for the second half of 20... |
| 15.02.2024 | Prostatype Genomics publishes year-end report for 2023 - supplement | Prostatype Genomics publishes year-end report for 2023 - supplement Thu, Feb 15, 2024 10:23 CET Report this content The supplement relates to the year-end report attachment, which was not attached to the previous press release. Prostatype G... |
| 10.01.2024 | Prostatype Genomics announces final outcome of the Rights Issue | Prostatype Genomics announces final outcome of the Rights Issue Wed, Jan 10, 2024 08:00 CET Report this content NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, ... |
Show more